Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBridgepoint Regulatory News (BPT)

Share Price Information for Bridgepoint (BPT)

Share Price is delayed by 15 minutes
Get Live Data
270.00    37.40 (16.08%)
Bid:
271.00
Ask:
271.60
Spread: 0.60 (0.221%)
Market Cap: £2.36b
BPT Live PriceLast checked at - London Stock Exchange

Intraday Bridgepoint Share Chart

Directorate Change

14 Apr 2025 07:00

RNS Number : 7746E
Bridgepoint Group plc
14 April 2025
Β 

Bridgepoint Group plc ("Bridgepoint" or the "Company")

Β 

Appointment of John Dionne and Michelle Scrimgeour as Independent Non-Executive Directors

Β 

14 April 2025

Β 

Bridgepoint is pleased to announce the appointment of John Dionne and Michelle Scrimgeour as independent non-executive directors with effect from 1 July 2025.Β 

Β 

Until he retired as a Senior Managing Director of Blackstone, John served as Global Head of the Private Equity Business Development and Investor Relations groups. He first joined Blackstone as the Founder and Chief Investment Officer of the Blackstone Distressed Securities Fund. Earlier in his career, John was a Partner and Portfolio Manager for Bennett Restructuring Funds, a Partner at Saugatuck Capital and a Director of Corporate Development for a predecessor of Thermo Fisher Scientific. He began his career at Price Waterhouse as a public accountant.

Β 

He is a Senior Lecturer of Business Administration at the Harvard Business School.

Β 

Michelle served as Chief Executive Officer of Legal & General Investment Management from July 2019 to December 2024. Before joining Legal & General, Michelle was Chief Executive Officer, EMEA, at Columbia Threadneedle Investments and was a member of the Executive Leadership Team of Ameriprise Financial. Earlier in her career she was Chief Risk Officer at M&G Investments and a Director of M&G Group Limited, which she joined in 2012 after a successful career at BlackRock. Michelle has served as Deputy Chair of the Investment Association, Chair of the Technology Working Group of the UK Government's Asset Management Taskforce and was a member of the FCA's Practitioner Panel.Β 

Β 

On appointment, Michelle will become the Chair of the Audit and Risk Committee, and John will become a member of the Audit and Risk Committee.Β 

Β 

Commenting on the appointments, Tim Score, Chair, said:

Β 

"I am delighted to welcome John and Michelle to the Board. Following a thorough appointment process, we are excited to have found two great candidates with extensive experience in asset management. Their respective experiences will be invaluable to the Bridgepoint Group as it continues to implement the strategy outlined at the Capital Markets Day in October 2024."

Β 

Β 

ENQUIRIES

Β 

Bridgepoint

Β 

Analysts and investors

Adam Key

Adam.Key@bridgepointgroup.com

+44 7833 748010

Β 

Media

Christian Jones

Christian.Jones@bridgepointgroup.com

+44 20 7034 3500

Β 

Β 

Finsbury Glover Hering (Public Relations Adviser to Bridgepoint)

Β 

James Murgatroyd / +44 20 7251 3801 / +44 7768 254 911

Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233

Anna Tabor / +44 20 7251 3801 / +44 7584 593 926

Bridgepoint-LON@fgsglobal.comΒ 

Β 

The following information is disclosed in accordance with UKLR 6.4.8 in respect of John Dionne and Michelle Scrimgeour:

Β 

Further information relating to John Dionne

Β 

Current publicly quoted company directorships

Β 

β€’

Cengage Learning Holdings II, Inc.

β€’

Clear Channel Outdoor Holdings, Inc.

Β 

Previous publicly quoted company directorships

Β 

β€’

Caesars Entertainment Corporation

β€’

Momentive Performance Materials, Inc.

β€’

Pelmorex Media, Inc.

β€’

Sequential Brands Group, Inc. (filed for bankruptcy protection on 31 August 2021)

Β 

Additional roles

Β 

Through John Dionne's activities as an institutionally-backed investor in the securities of companies in or near bankruptcy, he has held directorships in certain companies shortly before bankruptcy, or after its commencement. In addition to his directorship of Sequential Brands Group, Inc prior to its bankruptcy, as referred to above, he was appointed as a director of Crown Finance, US Inc and 65 of its subsidiaries following their filing for bankruptcy protection.

Β 

Further information relating to Michelle Scrimgeour

Michelle Scrimgeour was previously a director of Legal & General Group plc.Β 

Β 

Β 

There are no other disclosures to make pursuant to UKLR 6.4.8 in respect of either John Dionne or Michelle Scrimgeour.

Β 

Issued by Bridgepoint Group plc

LEI: 213800KFNMVI8PDZX472

Registered in England and Wales with registration number 11443992

Registered office: 5 Marble Arch, London, W1H 7EJ

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOAQFLFFEZLBBBF
Date   Source Headline
29th Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSRule 19.6(c) Confirmation
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 202611:15 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20253:31 pmRNSIssue of Equity and Total Voting Rights
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20254:30 pmRNSAdditional Listing
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:15 pmRNSDirector/PDMR Shareholding
17th Nov 20251:15 pmRNSDirector/PDMR Shareholding
14th Nov 20257:05 amRNSVariation of Lock-up Arrangements
14th Nov 20257:00 amRNSResults of Secondary Placing
13th Nov 20255:07 pmRNSProposed Secondary Placing of Ordinary shares
1st Sep 20257:00 amRNSTotal Voting Rights
19th Aug 20257:00 amRNSRule 19.6(c) Confirmation
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSHalf-year Report
2nd Jun 20257:00 amRNSShare Buyback Programme
15th May 20252:45 pmRNSResult of AGM
1st May 20257:00 amRNSTotal Voting Rights
14th Apr 20257:00 amRNSDirectorate Change
2nd Apr 20252:00 pmRNSDirector/PDMR Shareholding
2nd Apr 20252:00 pmRNSDirector/PDMR Shareholding
1st Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.